Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Suspending Alfacalcidol Supply; Chugai Curbs Further Products
July 21, 2021
- Sanofi to Transfer Plaquenil’s Japan Marketing Rights to Asahi Kasei on Oct. 1
July 20, 2021
- Ono Initiates PII Trial of BTK Inhibitor Velexbru for PCNSL in US
July 20, 2021
- Shionogi Bags Rights to COVID-19 Nasal Vaccines
July 20, 2021
- Kyosomirai Controls Shipments for Generic Calcitriol Amid Vitamin D3 Preparation Shortage
July 20, 2021
- Shipment Adjustments/Pauses for Choseido-Made Products Grow to 42
July 20, 2021
- Sawai’s Shipment Restrictions Now Reaches 385 Products
July 20, 2021
- Towa to Launch Cymbalta Generics on Aug. 30, Nipro on July 21/27
July 19, 2021
- Shionogi’s Peptide Vaccine Fails in PIII for Esophageal Cancer
July 19, 2021
- Guilty Rulings for 3 Wholesalers, Employees Now Final and Binding: Bid-Rigging Trial
July 19, 2021
- Arcalis Sees Opportunities in mRNA Drugs, Eyes Tens of Billions of Yen in CDMO Sales
July 19, 2021
- GHIT Fund to Bankroll 97 Million Yen in TB Drug Discovery Project
July 16, 2021
- Nichi-Iko to Cease Marketing of 9 Products Including Teva Takeda Drugs
July 15, 2021
- Nippon Shinyaku Sues Sarepta over DMD Therapy Patents in US
July 15, 2021
- Guilty Ruling for Ono Employees Now Final and Binding: Onoact Case
July 15, 2021
- Takeda Expecting Delay in Entyvio Biosimilar Entry in Europe: CFO
July 14, 2021
- Shionogi to Support Access to Cefiderocol in Low/Middle-Income Nations
July 14, 2021
- Eisai Taps Continuous Manufacturing for Tazverik, Eyes Its Use for Other Oncology Assets Too
July 14, 2021
- Astellas/Affinivax Pneumococcal Vaccine Delivers in PII, Gets Breakthrough Therapy Tag
July 14, 2021
- Takeda’s Takhzyro Adds Long-Term Efficacy Data on HAE Attack Reduction
July 14, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…